Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex


Change log
Authors
Merker, Matthias 
Kohl, Thomas A. 
Barilar, Ivan 
Andres, Sönke 
Fowler, Philip W. 
Abstract

Abstract: Background: A comprehensive understanding of the pre-existing genetic variation in genes associated with antibiotic resistance in the Mycobacterium tuberculosis complex (MTBC) is needed to accurately interpret whole-genome sequencing data for genotypic drug susceptibility testing (DST). Methods: We investigated mutations in 92 genes implicated in resistance to 21 anti-tuberculosis drugs using the genomes of 405 phylogenetically diverse MTBC strains. The role of phylogenetically informative mutations was assessed by routine phenotypic DST data for the first-line drugs isoniazid, rifampicin, ethambutol, and pyrazinamide from a separate collection of over 7000 clinical strains. Selected mutations/strains were further investigated by minimum inhibitory concentration (MIC) testing. Results: Out of 547 phylogenetically informative mutations identified, 138 were classified as not correlating with resistance to first-line drugs. MIC testing did not reveal a discernible impact of a Rv1979c deletion shared by M. africanum lineage 5 strains on resistance to clofazimine. Finally, we found molecular evidence that some MTBC subgroups may be hyper-susceptible to bedaquiline and clofazimine by different loss-of-function mutations affecting a drug efflux pump subunit (MmpL5). Conclusions: Our findings underline that the genetic diversity in MTBC has to be studied more systematically to inform the design of clinical trials and to define sound epidemiologic cut-off values (ECOFFs) for new and repurposed anti-tuberculosis drugs. In that regard, our comprehensive variant catalogue provides a solid basis for the interpretation of mutations in genotypic as well as in phenotypic DST assays.

Description

Funder: Joachim Herz Stiftung; doi: http://dx.doi.org/10.13039/100008662

Keywords
Research, Mycobacterium tuberculosis, Drug resistance, Benign mutations, Intrinsic resistance
Journal Title
Genome Medicine
Conference Name
Journal ISSN
1756-994X
Volume Title
12
Publisher
BioMed Central
Sponsorship
Wellcome Trust (214560/Z/18/Z)
Oscar II Jubilee Foundation (NA)
Health Innovation Challenge Fund (WT098600, HICF-T5-342)
German Center for Infection Research (NA)
Leibniz Science Campus “Evolutionary Medicine of the Lung” (EvoLung) (NA)